LPTX Leap Therapeutics Inc.

2.91
+0.04  (+1%)
Previous Close 2.87
Open 3.26
Price To Book 6.47
Market Cap 42786193
Shares 14,703,159
Volume 104,876
Short Ratio
Av. Daily Volume 70,470

SEC filingsSee all SEC filings

  1. 8-K - Current report 181234554
  2. 8-K - Current report 181193324
  3. 8-K - Current report 181171328
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171311
  5. 8-K - Current report 181131557

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data noted 46.7% ORR.
TRX518 in combination with gemcitabine chemotherapy or KEYTRUDA or Opdivo
Advanced solid tumors
Phase 1/2 data ESMO October 2018. 24% ORR.
DKN-01 + KEYTRUDA
Esophagogastric adenocarcinoma
Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.
DKN-01
Biliary tract cancer (BTC)
Phase 3 data fail October 2015
CureXcell
Diabetic Foot Ulcers
Phase 3 endpoint not expected to be met - August 19, 2015.
CureXcell
Venous Leg Ulcers
Phase 1/2 enrolling as of January 2017.
DKN-01
Esophageal cancer
Phase 2 interim data released at SITC November 2018. 47% ORR.
DKN-01 and Paclitaxel
Endometrial Cancer
Phase 1/2 trial to be initiated 1Q 2019.
TRX518 and avelumab
Solid tumors

SEC Filings

  1. 8-K - Current report 181234554
  2. 8-K - Current report 181193324
  3. 8-K - Current report 181171328
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171311
  5. 8-K - Current report 181131557
  6. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181063115
  7. 8-K - Current report 181060588
  8. 424B5 - Prospectus [Rule 424(b)(5)] 181060563
  9. UPLOAD [Cover] - SEC-generated letter
  10. CORRESP [Cover] - Correspondence